Medipost Posts 4.2% Revenue Growth and 67.9 Billion Won Loss

"Impact of Increased Clinical Trial Costs in the U.S. and Japan"

Medipost continued to record a consolidated loss due to increased costs associated with the expansion of global clinical trials. However, its domestic business remained profitable.

Medipost company logo image. Medipost

On March 19, Medipost announced that its consolidated revenue for 2025 reached 73.6 billion won, with an operating loss of 67.9 billion won. Revenue increased by 4.2% compared to the previous year. In contrast, on a separate basis, revenue was 76.8 billion won, and operating profit was 1.6 billion won, showing that the domestic business maintained stable profitability.

The widened loss is attributed to increased research and development expenses resulting from the ongoing Phase 3 clinical trials in the United States and Japan. Ordinary R&D expenses rose by around 30.5% compared to the previous year.

The rise in costs was influenced by preparations for the U.S. Phase 3 clinical trial. North American contract manufacturing (CMO) expenses had a significant impact, and initial setup activities such as establishing clinical trial site infrastructure, training research staff, and refining protocols were carried out. The company explained that it has established a foundation for rapid patient recruitment and dosing.

In Japan, Medipost is completing the Phase 3 clinical trial for Cartistem and is currently preparing the Clinical Study Report (CSR) required for the product approval application. Medipost plans to release the clinical results in the second quarter of 2026 and submit the application for Japanese approval in the latter half of the year.

Previously, in December 2025, the company secured a commercialization foundation by signing an exclusive local sales contract for Cartistem with Teikoku Seiyaku in Japan.

Medipost is also accelerating its entry into the U.S. market. In February this year, Medipost received IND approval for the U.S. Phase 3 clinical trial of Cartistem and is aiming for the first patient in (FPI) within the first half of the year. The company is targeting U.S. product approval by 2031.

This content was produced with the assistance of AI translation services.